company overview

OxThera is a biopharmaceutical company in late stage clinical development. The company develops products, based on its cell- and enzyme based proprietary technologies, for metabolic disorders of hyperoxaluria. OxThera's intellectual property portfolio includes worldwide patents for compositions as well as methods of use for the treatment of hyperoxaluria. OxThera's aim is to develop products to treat and prevent hyperoxaluria and kidney stones in Primary Hyperoxaluria and Enteric Hyperoxaluria. Oxabact^®, the lead candidate in OxThera's product pipeline, holds an orphan drug designation for Primary Hyperoxaluria in the US and in the EU. The company is based in Sweden and Florida.